INTRODUCTION

Glucagon-like peptide (GLP-1) receptor agonists are an emerging and increasingly popular class of medications used for the treatment of type 2 diabetes mellitus and, more recently, obesity. Since the expansion of approved uses to include weight loss, these medications have become increasingly popular. One mechanism of action of GLP-1 agonists is delayed gastric emptying.1 We describe two cases of patients taking GLP-1 receptor agonists that were found to have high volumes of complex gastric contents despite appropriate fasting per American Society of Anesthesiologists (ASA) practice guidelines for preoperative fasting.2 With the use of GLP-1 receptor agonists becoming increasingly more common, anesthesia professionals need to be aware of these medications and the potential risks they pose to patients receiving anesthesia.

CASE 1

A 60-year-old female presented for magnetic resonance imaging with sedation for claustrophobia. She had a history of hypertension and was overweight (body mass index [BMI] 28 kg/m²). The month prior, she started semaglutide (Ozempic, Novo Nordisk, Plainsboro, NJ) for weight loss (last dose 7 days prior to presentation). Despite fasting from solid food for more than 18 hours prior to evaluation, she described feeling “full.” A point-of-care gastric ultrasound was performed, which revealed solid gastric contents. The decision was made to cancel her imaging for fear of high risk of aspiration during the delivery of anesthesia.

Her other medications included: metformin, hydrochlorothiazide, pregabalin, oxycodone, 5 mg as needed (intermittent use with last dose the day prior to surgery), and sertraline. She had been fasting since the night before surgery.

Anesthesia proceeded with an uneventful induction of general anesthesia and intubation. After intubation, an orogastric tube was placed and gastric contents (Figure 1) were suctioned. After intubation, an orogastric tube was placed and gastric contents (Figure 1) were suctioned.

The case was uncomplicated from a surgical perspective. At case completion, the patient was transferred to the transport cart and sat up in anticipation of emergence. Shortly before she was ready for extubation, she developed large volume emesis of particulate matter that was consistent with what she reported eating several days prior to surgery (Figure 2). Fortunately, the endotracheal tube was still in place and her airway remained protected. Once emesis was cleared, she was uneventfully extubated. She was closely observed in the PACU and did not have evidence to suggest gastro-pulmonary aspiration and was therefore discharged home later that day.

DISCUSSION

GLP-1 receptor agonists are an increasingly popular class of medications being prescribed to patients. These medications have been described as a “breakthrough” for weight loss. The GLP-1 receptor is expressed in a diverse range of organ systems including gastrointestinal (GI) tract, pancreas, heart, liver, and brain. Stimulation of this receptor leads to weight loss, improved glycemic control in diabetic patients, and improved cardiac and renal outcomes. The primary mechanism of action is related to both activation of vagal afferent nerves innervating the stomach as well as direct binding to GLP-1 receptors on gastric mucosal cells leading to delayed gastric emptying.3 For diabetics, weight loss combined with stimulation of insulin secretion from pancreatic beta cells results in optimized hemoglobin A1c.3 Improvement in major acute cardiac events is likely related to both overall risk factor reduction (e.g., decreased glycerated hemoglobin level, blood pressure control, decreased body mass index, decreased low density lipoprotein cholesterol level, improved glomerular filtration rate, and the decreased albumin-to-creatinine ratio) as well as via direct stimulation of GLP-1 receptors on myocardium leading to better endothelial function and microvascular perfusion.4,5 GI side effects like nausea, vomiting, or diarrhea are

Figure 1: Depicts gastric contents in a patient on a GLP-1 agonist, who appropriately adhered to ASA fasting guidelines.

Figure 2: Depicts large volume emesis of particulate matter in a patient on a GLP-1 agonist that was consistent with what the patient reported eating several days prior to surgery.

See “GLP-1 Agonist Aspiration Risk,” Next Page
GLP-1 Agonists and Aspiration Risk

Table 1: Common GLP-1 Agonists.6,17

<table>
<thead>
<tr>
<th>GLP-1 Agonists</th>
<th>Clinical Dosing</th>
<th>Pharmacokinetics</th>
<th>Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exenatide (Byetta®, Bydureon®)</td>
<td>SQ, twice daily (IR), weekly (ER), uptitrated</td>
<td>3 hours, Renal</td>
<td>Associated with immune-mediated thrombocytopenia</td>
</tr>
<tr>
<td>Lixisenatide (Adlyxin®)</td>
<td>SQ, daily, uptitrated</td>
<td>3 hours, Renal</td>
<td>No longer available in United States</td>
</tr>
<tr>
<td>Semaglutide (Wegovy®, Ozempic®)</td>
<td>SQ, weekly, uptitrated</td>
<td>7 days, Renal</td>
<td>Approved (SQ formulation only) for weight loss</td>
</tr>
<tr>
<td>Tirzepatide (Mounjaro®)</td>
<td>SQ, weekly</td>
<td>5 days, Renal</td>
<td>Approved for weight loss</td>
</tr>
</tbody>
</table>

Table 2: Risk Factors for Aspiration.

<table>
<thead>
<tr>
<th>Esophageal Pathology</th>
<th>High risk for ileus/bowel dysmotility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Achalasia</td>
<td>Acute pancreatitis</td>
</tr>
<tr>
<td>Previous esophagectomy (e.g., Ivor Lewis)</td>
<td>Recent intra-abdominal surgery</td>
</tr>
<tr>
<td>Tracheoesophageal Fistula</td>
<td>Inpatient receiving opioids/prolonged bedrest</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intra-abdominal Obstruction</th>
<th>Emergency Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastric outlet, small bowel, colonic</td>
<td>Case with prolonged duration or complexity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Known, suspected, or induced gastroparesis (longstanding diabetes, neuromuscular disorders, medication—e.g., GLP-1 agonist)</th>
<th>Active GI Bleed</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Pregnancy</th>
<th>Case with prolonged duration or complexity</th>
</tr>
</thead>
</table>

increased risk of retained gastric contents in patients on these medications.15,16

The ASA’s Task Force on Preoperative Fasting recently released a consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists (Figure 3).17 For elective procedures, the expert group’s recommendation is to withhold daily dosed GLP-1 receptor agonists the day of the procedure and weekly-dosed formulations a week prior. On the day of the procedure, the recommendation is to ask specifically about GI symptoms, such as nausea, vomiting, abdominal pain, and abdominal distension, and consider delaying elective procedures in patients who are symptomatic. If patients are asymptomatic from a GI standpoint and medications were held per guidance, their recommendation is to proceed with the procedure. In patients without GI symptoms, but who have not held the medication as advised, the task force recommends proceeding with “full stomach” precautions with consideration for evaluating gastric volume by ultrasound to aid in decision-making. This group noted there is no evidence to suggest optimal duration of fasting.17 Other professional organizations such as the Society of Perioperative Assessment and Quality Improvement have also put forward consensus recommendations to hold GLP-1 receptor agonists on the day of surgery unless there is heightened concern for postoperative gut dysfunction.18 Given the long half-life of...
most medications within this class, stopping medications for at least 5 half-lives before surgery to allow normalization of gastric function is not feasible. Further, given the potential cardiovascular benefits and negligible risk for hypoglycemia, there is interest in continuing this class of medications without perioperative interruption.\(^{19}\)

At this point, the optimal approach to these patients still needs to be refined and hopefully additional studies will help guide our decision-making. A systematic approach to assessing risk in this patient population with a careful history of medication use, symptoms, and review of comorbidities is important. It may be prudent to re-evaluate traditional fasting guidelines in these patients. The use of gastric ultrasound to define gastric contents prior to anesthesia can be considered in patients presenting for anesthesia on these medications, when available.\(^{20-22}\)

In the setting of uncertainty regarding gastric contents, rapid sequence induction of anesthesia and gastric decompression prior to emergence could be considered. It should also be recognized that the risk for emesis and aspiration during emergence is also a real concern even with gastric decompression if the patient has residual solid gastric contents.

**CONCLUSION**

We present two cases of patients on GLP-1 receptor agonists with delayed gastric emptying despite appropriate preoperative fasting. We acknowledge it is difficult to ascertain the direct cause of the delayed gastric emptying in these patients as there were numerous risk factors. Nevertheless, with the use of GLP-1 receptor agonists becoming increasingly common, anesthesiology professionals need to be aware of these medications and the potential risks they pose to patients receiving anesthesia. Further studies investigating the safety of these agents as it relates to the management surrounding the peri-anesthetic period are needed.

William Brian Beam, MD, is an assistant professor of anesthesiology at Mayo Clinic, MN.

Lindsay R. Hunter Guevara, MD, is an assistant professor of anesthesiology at Mayo Clinic, MN.

The authors have no conflicts of interest.

**REFERENCES**


See “GLP-1 Agonist Aspiration Risk,” Next Page

**Figure 3: American Society of Anesthesiologists Consensus-Based Guidance on Preoperative GLP-1 Receptor Agonists Management**

**ASSESSMENT:**

Given concerns regarding reports of delayed gastric emptying related to GLP-1 receptor agonists, the ASA Task Force on Preoperative Fasting released guidance regarding preoperative management of these medications. For patients scheduled for elective procedures consider the following:

**DAY(S) PRIOR TO THE PROCEDURE:**

- Irrespective of indication (diabetes or weight loss), for patients on weekly dosing consider holding GLP-1 agonists a week prior to the procedure/surgery. For patients on daily dosing consider holding GLP-1 agonists on the day of the procedure/surgery.
- If GLP-1 agonists prescribed for diabetes management are held for longer than the dosing schedule, consider consulting an endocrinologist for bridging the anti-diabetic therapy to avoid hyperglycemia.

**DAY OF THE PROCEDURE:**

- If GI symptoms such as severe nausea/vomiting/retching, abdominal bloating, or abdominal pain are present, consider delaying elective procedure, and discuss the concerns of potential risk of regurgitation and pulmonary aspiration of gastric contents with the proceduralist/surgeon and the patient.
- If the patient has no GI symptoms, and the GLP-1 agonists have been held as advised, proceed as usual.
- If the patient has no GI symptoms, but the GLP-1 agonists were not held as advised, proceed with “full stomach” precautions or consider evaluating gastric volume by ultrasound, if possible, and if proficient with the technique. If the stomach is empty, proceed as usual. If the stomach is full or if gastric ultrasound is inconclusive or not possible, consider delaying the procedure or treat the patient as “full stomach” and manage accordingly. Discuss the concerns of potential risk of regurgitation and pulmonary aspiration of gastric contents with the proceduralist/surgeon and the patient.
- There is no evidence to suggest the optimal duration of fasting for patients on GLP-1 agonists. Therefore, until we have adequate evidence, we suggest following the current ASA fasting guidelines.
Guidance for Perioperative Care in Patients on GLP-1 Agonists

From “GLP-1 Agonist Aspiration Risk,” Preceding Page


